Molecular testing has become a mandatory component of the non-small cell lung cancer
(NSCLC) management. The detection of EGFR, BRAF and MET mutations as well as the …

The administration of many cancer drugs is tailored to genetic tests. Some genomic events,
eg, alterations of EGFR or BRAF oncogenes, result in the conformational change of the …

Introduction BRAF is a serine-threonine kinase implicated in the regulation of MAPK
signaling cascade. BRAF mutation-driven activation occurs in approximately 2–4% of …

Background Despite the progress in the development of next‐generation sequencing (NGS),
diagnostic PCR assays remain to be utilized in clinical routine due to their simplicity and low …

Molecular genetic analysis is an integral part of colorectal cancer (CRC) management. The
choice of systemic therapy for CRC is largely based on the results of tumor molecular …

ABSTRACT Introduction RAS-RAF-MEK-ERK signaling is implicated in tumor development
by promoting cell proliferation and other cancer hallmarks. MEK1/2 kinases are up-regulated …

The management of lung cancer (LC) requires the analysis of a diverse spectrum of
molecular targets, including kinase activating mutations in EGFR, ERBB2 (HER2), BRAF …

Молекулярно-генетическая диагностика-неотъемлемый элемент планирования
лечения пациентов с раком толстой кишки (РТК). Выбор системной терапии при РТК …

Молекулярно-генетическое тестирование с целью индивидуализированного
назначения терапии является неотъемлемым компонентом современной практической …

Molecular genetic diagnostics is an essential element to plan for management of colorectal
cancer (CRC) patients. The choice of systemic treatment for CRC is impossible without …